Eli Lilly and Company operates primarily in a single business segment focused on the discovery, development, and commercialization of human pharmaceutical products. The company's portfolio spans several major therapeutic areas, with a strong emphasis on cardiometabolic health, oncology, immunology, and neuroscience. Key products include blockbuster medications such as Mounjaro, Zepbound, Trulicity, Verzenio, and Jardiance. Geographically, Eli Lilly maintains a massive global footprint, operating manufacturing and research facilities across North America, Europe, and Asia, and distributing its medicines in approximately 125 countries. The company's competitive position is underpinned by its extensive research and development capabilities, which have historically yielded pioneering treatments ranging from the first mass-produced insulin to modern biologics.
